Novartis

Positive Review

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

Qiagen and Foundation Medicine will develop tissue- and plasma-based companion tests to identify best responders to the PI3K inhibitor alpelisib

The CDx would guide use of Novartis' BYL719 (alpelisib) in combination with fulvestrant for men and postmenopausal women with HR+/HER2- breast cancer.

The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.

During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.

The collaboration agreement includes support for development, regulatory submission, and commercialization of tests to guide use of Novartis' drug portfolio.

The San Diego Union-Tribune reports on the difficulties health insurers face with new gene and cell therapies.

To the Wrong Cell

Researchers report on a case in which a CAR T-cell therapy was mistakenly delivered to a cancer cell, Stat News writes.

Single-cell RNA sequencing from mouse trachea and human bronchial epithelial cells unearthed new cell types, including ionocytes enriched for CFTR expression.

Risk With the Fix?

Two research teams warn that CRISPR-based gene editing could boost cancer risk by affecting p53 function, according to Stat News.

Pages

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.